Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of E6011 in active Crohn's disease
2018-002109-70Phase 2Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing E6011 with Placebo (2 arms). Started Nov 2018; status: completed.
02
Drugs
quetmolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2018-002109-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002109-70.